Botulinum Toxin (A & B) comment watch save
BreastfeedingPediatric

  • TRADE NAMES: Azzalure (Galderma); Bocouture (Merz); Botox (Allergan); Dysport (Ipsen); Myobloc (Solstice); Neurobloc (Eisai); Vistabel (Allergan); Xeomin (Merz)
  • INDICATIONS: Blepharospasm, hemifacial spasm, spasmodic torticollis, sialorrhea, hyperhidrosis, strabismus, oromandibular dystonia, cervical dystonia, spasmodic dysphonia, chronic migraine; urinary incontinence in people with neurologic conditions such as spinal cord injury and multiple sclerosis who have overactivity of the bladder; cosmetic application for wrinkles
  • SYNONYM: OnabotulinumtoxinA
  • CLASS: Acetylcholine inhibitor, Neuromuscular blocker, Ophthalmic agent, toxin
  • HALF-LIFE: 3–6 months

Distant spread of toxin effect - postmarketing reports indicate that all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing diffculties. These symptoms have been reported hours to weeks after injection.

An antitoxin is available in the event of overdose or misinjection.

DISTANT SPREAD OF TOXIN EFFECT

See full prescribing information for complete boxed warning.

Please login to view the rest of this drug profile.

    DRUG REVIEW ARTICLE

    Click on the DRUG REVIEW ARTICLE tab (above) to see a review of onabotulinumtoxinA in the Taylor & Francis journal Expert Opinion on Drug Safety.

    (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 01/22/2025

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric